<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3517">
  <stage>Registered</stage>
  <submitdate>11/04/2012</submitdate>
  <approvaldate>11/04/2012</approvaldate>
  <nctid>NCT01577173</nctid>
  <trial_identification>
    <studytitle>A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck</studytitle>
    <scientifictitle>A Phase II, Open-Label, Randomized Study of MEDH7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Progressed During or Following Platinum-based Chemotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-005539-22</secondaryid>
    <secondaryid>GO28076</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Head and Neck Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MEHD7945A
Treatment: drugs - cetuximab

Experimental: A: MEHD7945A - 

Active Comparator: B: Cetuximab - 


Treatment: drugs: MEHD7945A
1100 mg iv every 2 weeks

Treatment: drugs: cetuximab
400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (tumor assessments according to RECIST criteria)</outcome>
      <timepoint>approximately 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response: complete response or partial response</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease control: complete response, partial response or stable disease</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of objective response</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disease progression</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>approximately 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Cmax/Cmin</outcome>
      <timepoint>Pre-dose and 30 min after end of infusion on Day 1 of Cycles 1, 2, 3, and 4, and at treatment completion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity: anti-MEHD7945A levels</outcome>
      <timepoint>Pre-dose on Day 1 of Cycles 1 and 4, and at treatment completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, &gt;/= 18 years of age

          -  Histologically confirmed Stage III or IV recurrent/metastatic squamous cell carcinoma
             of the head and neck (R/M SCCHN)

          -  Progressive disease on or after first-line platinum-based chemotherapy regimen for R/M
             SCCHN (maximum of 6 cycles)

          -  No more than one platinum-based chemotherapy regimen for R/M SCCHN is allowed

          -  Prior platinum-based treatment as definitive chemo/radiotherapy for locally advanced
             disease is allowed if completed/terminated &gt;/= 6 months before the platinum-based
             regimen for R/M SCCHN

          -  Consent to provide archival tumor tissue for biomarker testing

          -  Measurable disease per RECIST v1.1

          -  ECOG performance status of 0, 1 or 2

          -  Adequate hematologic, renal and liver function</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Nasopharyngeal cancer

          -  Prior treatment with an investigational or approved agent for the purpose of
             inhibiting HER family members

          -  This includes but is not limited to cetuximab, panitumumab, erlotinib, geftinib, and
             lapatinib

          -  Prior treatment with an EGFR inhibitor is allowed if it was administered as part of
             definitive therapy for locally advanced disease and completed &gt;/=1 year before study
             enrollment

          -  Leptomeningeal disease as the only manifestation of the current malignancy

          -  Active infection requiring iv antibiotics

          -  Active autoimmune disease that is not controlled by non-steroidal anti-inflammatory
             drugs

          -  Current severe, uncontrolled systemic disease (e.g. clinically significant
             cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; bone
             fractures)

          -  History of heart failure or serious cardiac arrhythmia

          -  History of myocardial infarction within 6 months of Cycle 1, Day 1

          -  Clinically significant liver disease, including active viral, alcoholic or other
             hepatitis, cirrhosis, or current alcohol abuse

          -  HIV infection

          -  Primary central nervous system (CNS) malignancy or untreated/active CNS metastases
             (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)

          -  Pregnant or lactating women

          -  Malignancies other than SCCHN within 5 years prior to randomization, with the
             exception of adequately treated basal or squamous cell skin cancer and carcinoma in
             situ of the cervix</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>122</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital> - Darlinghurst</hospital>
    <hospital> - Waratah</hospital>
    <hospital> - Wollongong</hospital>
    <hospital> - Brisbane</hospital>
    <hospital> - Kurralta Park</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2298 - Waratah</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Namur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Ruse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clichy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villejuif</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Debrecen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szolnok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Friuli-Venezia Giulia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piemonte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Salamanca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sutton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This phase II, open-label, randomized study will evaluate the efficacy and safety of
      MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of
      the head and neck who have progressed during or following platinum-based chemotherapy.
      Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2
      weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients
      treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation
      of progressive disease and upon meeting eligibility criteria. Anticipated time on study
      treatment is until disease progression or intolerable toxicity occurs.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01577173</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>